Dec 23 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved Allergan Plc’s drug for treating acute migraine in adults.
The drug, Ubrelvy, is the first oral version of a new class of drugs called CGRP inhibitors to win the FDA's approval for treating the neurological disease. (bit.ly/2QeY1b7)
The new class of drugs acts by interfering with CGRP, a protein involved in causing severe headaches.
Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli